Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: Pharmaceutical Drug Production in Russia (February 2019)

Thursday, March 28, 2019

Between January and February 2019, Russia produced 53.6 bln RUB worth of pharmaceuticals (dispatch prices, VAT included), which is in monetary terms 14.3% higher than that of the same period in 2018. In physical terms, the dynamics are -1.5%, with 651.5 mln units.

The dynamics of the OTC drug production in physical terms are -4.6% for the period, while those of the Rx drug production are +3.7%. Among the top 10 EphMRA groups of second level which are leaders in physical terms, systemic antivirals (-43%), antirheumatics for local administration (-16%), and vitamins (-13%) have the worst dynamics. Among the top 10 OTC drug-producing companies with the highest dynamics in physical terms, Tatkhimpreparaty and Ozon have the biggest drop, -52% and -36%, respectively. Despite the overwhelmingly negative dynamics, there are still companies with positive dynamics. For instance, Samaramedprom has a 2.4 times increase, which is the best dynamics among the OTC drug-producing companies.

As for Rx drugs, the following categories have the worst dynamics in physical terms: solutions for intravenous admission (-36%), antiseptics and disinfectant drugs (-22%), and systemic antibacterials (-21%.) Diuretics (+58%) and anti-inflammatory and antirheumatics (+38%) have the highest dynamics. Groteks and Ozon have the highest dynamics in physicals terms, with +52% and +30%, respectively.

Read more about pharmaceutical drug production in Russia (January 2019) here:

Dynamics of pharmaceutical drug production in Russia, including production of pharmaceuticals of foreign companies on owned or contract plants, in physical (units) and monetary terms (RUB, VAT included) (January 2018 – February 2019)